Article ID Journal Published Year Pages File Type
10072140 American Journal of Ophthalmology 2005 8 Pages PDF
Abstract
Over the 3 months of treatment, Trav/Tim produced clinically relevant IOP reductions in patients with open-angle glaucoma or ocular hypertension that were greater than those produced by either Trav or Tim alone. The clinical results that Trav/Tim was safe and well tolerated with an incidence of adverse events was comparable to the results of Trav or Tim alone. Trav/Tim provides both more effective IOP reduction than its components and the benefits of once-daily dosing.
Related Topics
Health Sciences Medicine and Dentistry Ophthalmology
Authors
, , , , , , ,